Resultados de la clasificación Gynecologic Imaging Reporting and Data System para la catalogación de masas anexiales

ResumenObjetivoDeterminar el valor de la clasificación Gynecologic Imaging Reporting and Data System (GI-RADS) para discriminar las masas anexiales malignas de las benignas.Material y métodosEstudio observacional retrospectivo de 87 pacientes operadas en nuestro hospital con un total de 98 masas anexiales. Se clasificaron mediante el sistema GI-RADS y se compararon con la histología definitiva.ResultadosGI-RADS 3: 75 casos. En todos los casos GI-RADS 3, el diagnóstico definitivo fue de benignidad. GI-RADS 4: 11 casos. En el 27,27% de los casos el diagnóstico definitivo fue de malignidad (un carcinoma y 2 tumores borderline), y en el 72,72% de los casos, de benignidad. GI-RADS 5: 12 casos. En el 91,66% de los casos el diagnóstico histológico informó de malignidad (10 carcinomas y un tumor borderline).DiscusiónNuestros resultados refuerzan la fiabilidad de la clasificación para catalogar correctamente las tumoraciones malignas en los grupos GI-RADS 4 y 5.

ObjectiveTo assess the clinical usefulness of the Gynecologic Imaging Reporting and Data System (GI-RADS) classification to distinguish between benign and malignant adnexal masses.Material and methodsA retrospective study was conducted in 98 adnexal masses in 87 patients who underwent surgery in our hospital. The masses were classified according to GI-RADS and the results were compared with their definitive histologic diagnosis.ResultsSeventy-five masses were classified as GI-RADS 3. All GI-RADS 3 masses had a definitive histologic diagnosis of benignity. Eleven masses were GI-RADS 4, of which 27.27% had a definitive histologic diagnosis of malignancy (one carcinoma and 2 borderline tumors) and 72.72% were diagnosed as benign. Twelve masses were GI-RADS 5, of which 91.66% had a definitive histologic diagnosis of malignancy (10 carcinomas and one borderline tumor).DiscussionOur results support the reliability of the GI-RADS classification to correctly identify malignant tumors in GI-RADS 4 and 5.